Treatment for bacterial infection

Abstract

The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

What is claimed is: 
     
         1 . A method for treating a bacterial infection in a subject, comprising administering a therapeutically effective amount of a topical formulation of besifloxacin to a subject in need thereof, wherein said formulation comprises besifloxacin in an amount from about 1% to about 50% (w/w or w/v). 
     
     
         2 . The method of  claim 1 , wherein the method further comprises administering a second agent to the subject. 
     
     
         3 . The method of  claim 2 , wherein the second active agent is adapalene. 
     
     
         4 . The method of  claim 2 , wherein the besifloxacin and the second active agent are formulated in same composition. 
     
     
         5 . The method of  claim 1 , wherein the bacterial infection is caused by a drug resistant bacterial strain. 
     
     
         6 . The method of  claim 1 , wherein the bacterial infection is acne caused by  P. acnes.    
     
     
         7 . The method of  claim 6 , wherein the acne is drug resistant acne. 
     
     
         8 . The method of  claim 2 , wherein the bacterial infection is caused by a drug resistant bacterial strain. 
     
     
         9 . The method of  claim 2 , wherein the bacterial infection is acne caused by  P. acnes.    
     
     
         10 . The method of  claim 9 , wherein the acne is drug resistant acne. 
     
     
         11 . A method of treating acne, including drug resistant acne, comprising administering a therapeutically effective amount of besifloxacin to a subject in need thereof. 
     
     
         12 . The method of  claim 11 , wherein the method further comprises administering a second agent to the subject. 
     
     
         13 . The method of  claim 12 , wherein the second active agent is adapalene. 
     
     
         14 . The method of  claim 12 , wherein the besifloxacin and the second active agent are formulated in same composition. 
     
     
         15 . A method for treating inflammation associated with a bacterial infection, such as acne, comprising administering a therapeutically effective amount of a topical formulation of besifloxacin to a subject in need thereof, wherein said formulation comprises besifloxacin in an amount from about 1% to about 50% (w/w or v/v). 
     
     
         16 . The method of  claim 15 , wherein the method further comprises administering a second agent to the subject. 
     
     
         17 . The method of  claim 16 , wherein the second active agent is adapalene. 
     
     
         18 . The method of  claim 16 , wherein the besifloxacin and the second active agent are formulated in same composition. 
     
     
         19 . A Dual Action Rational Therapeutic (DART) molecule, wherein:
 (i) the DART molecule has two distinct mechanisms of action for treatment or prevention of bacterial infections;   (ii) the DART molecule has two distinct anti-bacterial mechanisms of action or an anti-bacterial and an anti-inflammatory action;   (iii) the DART molecule has two distinct anti-acne mechanisms of action;   (iv) the DART molecule comprises a quinolone and a nitro-heterocycle;   (v) the DART molecule comprises a beta-lactam and a nitro-heterocycle;   (vi) the DART molecule comprises a beta-lactam and a quinolone; or   (vii) the DART molecule comprises two chemical domains, each said chemical domain binding to a distinct active site in target cells, wherein said chemical domains are bound together through a third domain.   
     
     
         20 . The DART molecule of  claim 19 , wherein the DART molecule is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         21 . A method of treating a bacterial infection in a subject comprising administering a therapeutically effective amount of a DART molecule of  claim 19  to a subject in need thereof. 
     
     
         22 . The method of  claim 21 , wherein the bacterial infection is by a drug-resistant bacterial strain.